
![]() |
Investigator Awards in Health Policy Research 55 Commercial Ave. Third Floor New Brunswick, NJ 08901-1340 |
Tel: (732) 932-3817 Fax: (732) 932-3819 Email: depdir@ifh.rutgers.edu www.investigatorawards.org |
![]() www.rwjf.org |
Section Info![]() |
|
The U.S. Food and Drug Administration (FDA) is one of the world’s most powerful regulatory agencies. No new drug can be marketed legally in the United States unless the FDA declares it to be “safe and effective” for its intended uses. Having set the scientific standards and processes for drug approval, the FDA has played a key role in the industry’s evolution worldwide and shapes how pharmaceutical companies develop, market, and manufacture their products. More subtly, the FDA undergirds public confidence in pharmaceuticals.
According to Daniel Carpenter, the Allie S. Freed Professor of Government and Director of the Center of American Political Studies at Harvard University, the primary source of the agency’s power is its professional and scientific reputation, carefully cultivated over time and guarded by FDA career officials.
But how did the FDA’s reputation invest it with so much influence? And how exactly does the FDA wield its extraordinary power? Carpenter has probed these and other intriguing questions about the FDA’s history, evolution and behavior, more deeply perhaps than any other scholar ever.
Carpenter traces the roots of his interest in the curious and sometimes troubled intermingling of regulation, power, and politics to his grandfather, Edward Krumbiegel, who served for 33 years as health commissioner for the city of Milwaukee, Wisconsin. The stories he heard from his grandfather and from his mother, Kathleen, who worked as a radiologist, about battles over fluoridation, pest control, and other public health issues led him to understand early on that health policy does not emerge purely or even largely from the world of science. “I learned that public health was an endeavor not only of science, but of politics in its best and worst aspects,” Carpenter says.
Read More... (PDF)![]() |
|
Section Info
Go to: All Books | Book Chapters | Journal Articles![]() |
|
Daniel Carpenter describes how the FDA cultivated a reputation for competence and vigilance throughout the last century, and how this organizational image has enabled the agency to regulate an industry as powerful as American pharmaceuticals while resisting efforts to curb its own authority. Carpenter explains how the FDA's reputation and power have played out among committees in Congress, and with drug companies, advocacy groups, the media, research hospitals and universities, and governments in Europe and India. He shows how FDA regulatory power has influenced the way that business, medicine, and science are conducted in the United States and worldwide. Along the way, Carpenter offers new insights into the therapeutic revolution of the 1940s and 1950s; the 1980s AIDS crisis; the advent of oral contraceptives and cancer chemotherapy; the rise of antiregulatory conservatism; and the FDA's waning influence in drug regulation today.
Reputation and Power demonstrates how reputation shapes the power and behavior of government agencies, and sheds new light on how that power is used and contested.
Daniel P. Carpenter is the Allie S. Freed Professor of Government at Harvard University. He is the author of The Forging of Bureaucratic Autonomy: Reputations, Networks, and Policy Innovation in Executive Agencies, 1862-1928 (Princeton).
Endorsements:
"Reputation and Power is by far the most thorough and penetrating study of the most powerful and important regulatory agency in the world--the U.S. Food and Drug Administration--and one of the best studies of any American regulatory agency. The book is essential reading for anyone seriously interested in American politics, public policy, administrative institutions, or health and medicine. This is an extraordinary work."--Paul Quirk, University of British Columbia
"Carpenter has integrated an understanding of the FDA's legal history and programmatic responsibilities with a perceptive grasp of the personalities who shaped that history. His work surpasses in depth and scope all other accounts of the FDA with which I am familiar. No one in the future will be able to write seriously about the FDA's drug approval system without taking account of Carpenter's work. His curiosity knows no limits."--Richard A. Merrill, professor emeritus, University of Virginia
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
|
To show healthy city planning in action, Corburn examines collaborations between government agencies and community coalitions in the San Francisco Bay area, including efforts to link environmental justice, residents' chronic illnesses, housing and real estate development projects, and planning processes with public health. Initiatives like these, Corburn points out, go well beyond recent attempts by urban planners to promote public health by changing the design of cities to encourage physical activity. Corburn argues for a broader conception of healthy urban governance that addresses the root causes of health inequities.